NTLA-5001 for Acute Myeloid Leukemia
Research type
Research Study
Full title
Phase 1/2a, Single Dose Study Investigating NTLA 5001 in Subjects with Acute Myeloid Leukemia
IRAS ID
1003829
Contact name
Ishita Kalamkar
Contact email
Sponsor organisation
Intellia Therapeutics, Inc.
Eudract number
2021-001231-13
Clinicaltrials.gov Identifier
Research summary
Summary of Research
The purpose of this study is to learn about the effects of a new investigational medicine, NTLA-5001, to see how safe NTLA-5001 is for patients with Acute Myeloid Leukemia (AML), and to find the best dose for further AML research. NTLA-5001 is made from a patient’s own cells, which are changed to kill cancer cells. The study consists of 2 phases: dose escalation and dose expansion. Up to 4 dose levels of NTLA-5001 will be investigated. This is an open-label study. This means that patient, the study doctor, study staff, and Intellia will know the study medicine and the doses that you are given.
Approximately 54 adults will take part in this study at approximately 10 study sites in the United States and United Kingdom. Each patient’s participation in this study will last approximately 117 weeks.
Intellia Therapeutics, Inc. is sponsoring this study.REC name
North East - York Research Ethics Committee
REC reference
21/NE/0101
Date of REC Opinion
16 Nov 2021
REC opinion
Further Information Favourable Opinion